Novartis' Pipeline Broke Over a Week. What It Buys Next Decides Whether the Stock Re-rates.

Novartis just had the worst week — by some measures the worst single day — in its modern history as a public company. On Tuesday the Swiss drugmaker said del-desiran, a medicine for a rare muscle-wasting disease that it acquired when it paid $12 billion for Avidity Biosciences, failed a late-stage trial. That came days after pelacarsen, a cholesterol drug investors had treated as a potential multibillion-dollar blockbuster, also missed its goal. The shares fell roughly 15% over five sessions, and the debate has now moved to one question: what does Novartis buy next?

That question deserves a closer look, because the answer decides whether this selloff is a reset or the start of a bigger problem.

Why the pipeline news hit so hard

Novartis spent years selling a specific story. Its biggest older drugs — heart-failure treatment Entresto among them — were losing patent protection, a stretch management itself calls the largest patent expiry in the company's history. The offset was supposed to come from a pipeline of newer medicines, some built in-house and some bought.

Two of the best proofs of that plan collapsed in a week. Pelacarsen targeted a harmful type of cholesterol called Lp(a) and was meant to be a major new drug; its failure cast doubt on the whole class of drugs, not just Novartis'. Del-desiran was bigger still. The $12 billion Avidity purchase was supposed to deliver a platform producing several rare-disease drugs, with del-desiran the crown jewel — one analyst had assigned it a 60% probability of success and peak sales of more than $3 billion. It failed to beat placebo on the study's main measure of hand muscle stiffness.

This is where the M&A spotlight comes from. With the growth-by-pipeline narrative broken, the only lever left in the story is buying growth. And the del-desiran outcome is a direct warning about that lever: a "bolt-on" deal is only low-risk until its central asset fails, and a $12 billion bet whose key drug holds a coin-flip-to-better probability of success is not actually a small, safe wager.

The cash engine that did not break

Here is the distinction the market is only partly drawing. Two different things happened this week, and they are not the same.

The pipeline-growth story broke. That is real business pain — two products that will not now be sold, and real money spent acquiring them. But the machine that funds the deals did not break. Novartis still generates roughly $15 billion of free cash flow a year, about 28% of sales, on operating margins near 30%. It has raised its dividend for 19 consecutive years. It reaffirmed its target of 5-6% compound annual sales growth through 2030 even after the failures.

At the current price, that engine is the bridge. The stock trades at about 17 times forward earnings and carries a free-cash-flow yield of roughly 6% — a multiple that increasingly looks like a market assigning close to zero value to the pipeline upside that just collapsed. The old risk profile is being priced in at a time when the durable cash generation underneath is still intact. Tape pain has run ahead of business pain in that specific sense.

What would make the cash engine worth more

The honest bear case is not really about this week. It is that revenue grew only about 3% over the past year while the patent cliff is still biting, that net debt has climbed toward $40 billion in large part to fund the acquisitions, and that several analysts publicly doubt Novartis can hit its own growth target. Cheap-looking cash flow is not by itself a reason to own a stock — it can just as easily be spent badly.

So the rerating comes down to one thing: whether Novartis converts that $15 billion a year into durable growth without more value-destroying clinical flops. It has a few live candidates left — an anti-inflammatory drug called remibrutinib, newer neuromuscular medicines from the Avidity deal, and the oncology franchise. If those deliver and management stays disciplined about price, the reset leaves room for surprise because the market bar is now low and the cash engine still clears it. If another big bet fails, or the free-cash-flow path cracks, the low multiple is doing what depressed multiples sometimes do: describing permanent deterioration rather than an opportunity.

That is the tripwire. Fixing a number of dollars or a target date would be manufacturing a certainty the evidence does not support; the honest version is a condition. Novartis's shares fell this week because the growth pipeline let it down, not because the company stopped making money. Whether they recover depends on whether the next round of deals rebuilds the growth story — or repeats the last one.